Orochem has been awarded a Phase 1 contract by NIH to develop LPC-DHA as an effective molecule to transport DHA into brain.
Alzheimer’s disease (AD) and related dementia (ADRD) are adversely impacting the healthy lifespan in our aging population. Fish oil has been suggested to improve AD/ADRD outcomes. The omega 3 fatty acids (Om3FA) in fish oil in particular DHA (docosahexaenoic acid) is a key molecule. Some data exists that DHA is beneficial for protection against age related cognitive decline and related dementia such as AD. However, current dietary supplements of Om3FA do not appreciably increase DHA levels in the brain. Orochem Technologies Inc. has been awarded a Phase 1 contract by NIH to develop LPC-DHA as an effective molecule to transport DHA into the brain.
Orochem will utilize its chromatography technology to produce LPC-DHA on large scale using variety of feedstocks. Through collaboration with the University of Illinois at Chicago, with expertise in Om3FA and mouse models, and Orochem’s expertise in chemical separation and Om3FA isolation techniques, we are poised to test the efficacy of this novel treatment. Moreover, we are prepared for Phase 2 studies, which will focus on development of pilot scale production/isolation processes of this modified DHA. This will eventually lead to marketing and commercialization to protect and/or prevent against AD development in Phase 3.